Indogulf Cropsciences Ltd (IGCL)

Chemicals · Agro Chemicals · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹71.21 ↓ 32.12% (1Y)

🎯 Key Takeaways

Indogulf Cropsciences Ltd is in a recovery phase following a prolonged earnings decline, with sequential revenue growth and margin stabilization emerging in Q1 FY27 after multiple quarters of contraction. The company is executing a strategic shift toward higher-margin biologicals and global markets, supported by operational improvements and capital discipline.
Revenue grew 11.8% QoQ to ₹169 in Q1FY27.
⚠️ Persistent profitability pressure despite revenue recovery, with PAT margins negative in absolute terms and reliant on cost optimization.

Market Cap

₹450

P/E Ratio

13.8

P/B Ratio

1.64

ROE

14.0%

ROCE

14.0%

Debt/Equity

0.80

Promoter

69.0%

✨ Ask AI About IGCL 📊 Interactive Charts

📖 The Story

Indogulf Cropsciences Ltd is in a recovery phase following a prolonged earnings decline, with sequential revenue growth and margin stabilization emerging in Q1 FY27 after multiple quarters of contraction. The company is executing a strategic shift toward higher-margin biologicals and global markets, supported by operational improvements and capital discipline. However, profitability remains pressured, requiring sustained execution to validate the turnaround narrative.

📰 What's Happening

Management has prioritized operational efficiency and portfolio expansion, as highlighted in the Q1 FY27 earnings call and board-approved results. The company corrected presentation errors in its investor deck without altering financial outcomes, underscoring transparency. Key initiatives include deepening farmer engagement, expanding biologicals, and improving manufacturing utilization, which reached 70% in Q1 FY27. Additionally, the company successfully deployed all Rs 200 crore from its IPO with zero material deviation, as confirmed by Brickwork Ratings, reinforcing governance and capital allocation credibility.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	248	116	151	169
Operating Profit	29	9	17	7
OPM %	11.8%	7.7%	11.1%	4.0%
Net Profit	21	4	12	2
EPS	₹1.73	₹0.77	₹2.30	₹0.38

Revenue has shown sequential recovery, rising to ₹1,685 million in Q1 FY27 from ₹116 million in Dec 2025, driven by improved utilization and pricing. However, profitability remains volatile, with PAT declining 38% YoY despite margin expansion to 6% EBITDA and gross margin improvement to 28%. Operating performance reflects ongoing restructuring, with EBITDA turning positive after prior losses, but net income pressure persists due to high fixed costs and foreign exchange impacts.

🔮 Management Outlook & What's Next

Management expects continued growth in agro-solutions and biologicals, with a focus on deepening farmer engagement and expanding global footprint. In the Q1 FY27 earnings call, they emphasized improving operational efficiencies and margin expansion as critical levers for sustainable profitability. No formal financial guidance was provided, but the narrative centers on execution discipline rather than top-line acceleration in the near term.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2024	Mar 2025	Mar 2026	Mar 2026
Equity Capital	24	49	63	63
Reserves	208	226	377	396
Borrowings	159	220	208	183
Total Liabilities	542	688	866	823
Fixed Assets	43	48	42	42
Investments	0	0	15	12
Total Assets	542	688	866	823

The balance sheet shows stable equity at ₹63 crore with reserves growing to ₹396 crore, indicating retained earnings and capital resilience. Borrowings declined to ₹183 crore by March 2026 from ₹220 crore in the prior year, signaling active deleveraging. Total assets peaked at ₹866 crore in March 2026, reflecting investments in infrastructure and working capital, while the company maintains a manageable D/E ratio of 0.80, supporting financial flexibility.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	-15
Investing	-40
Financing	+61
Net Cash Flow	+7

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	69.0%	69.0%	69.0%	69.0%
FII	0.4%	0.2%	0.2%	0.2%
DII	6.2%	4.4%	4.4%	4.3%
Public	19.6%	21.1%	20.1%	20.3%
# Shareholders	24,798	24,867	23,867	23,768

Institutional interest remains low, with FII holding flat at 0.23-0.24% and DII declining slightly from 6.23% to 4.36% over the past year, suggesting limited investor confidence. Promoter holding is stable at 69.05%, with no pledging observed. The shrinking public float and rising shareholder count (23,768) indicate retail stability but limited new institutional inflows, potentially constraining liquidity and valuation re-rating.

⚖️ Peer Comparison — Agro Chemicals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
UPL	47,750	23.4	11.4%	6.7%	0.64
PIIND	36,230	31.1	13.3%	10.4%	0.02
SUMICHEM	25,674	44.3	23.1%	17.1%	0.00
BAYERCROP	17,940	371.7	3.3%	1.2%	0.00
SHARDACROP	7,113	11.4	25.8%	20.0%	0.00
DHANUKA	4,409	15.1	27.5%	21.2%	0.03
RALLIS	4,032	24.6	12.9%	9.7%	0.03
NACLIND	3,948	337.1	6.0%	1.8%	0.44
BHAGCHEM	3,496	127.2	6.1%	3.9%	0.33
GSPCROP	2,890	25.3	22.5%	21.9%	0.66

🔗 Peer Stock Analyses

UPL PIIND SUMICHEM BAYERCROP SHARDACROP

⚠️ Risk Factors

1. Persistent profitability pressure despite revenue recovery, with PAT margins negative in absolute terms and reliant on cost optimization. 2. Low institutional ownership and thin trading volumes may amplify volatility. 3. Foreign exchange volatility could impact margins given export exposure. 4. Execution risk in scaling biologicals and global operations amid competitive agrochemical pricing pressures.

📋 Recent Filings

🧠 Analyst's Read

Indogulf Cropsciences is undergoing a gradual turnaround with early signs of operational stabilization, but profitability remains the key monitorable. Investors should watch for sustained margin improvement and clearer traction in biologicals during upcoming investor engagements. The company's capital discipline and fund utilization oversight are positives, but near-term earnings volatility limits near-term re-rating potential.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on IGCL

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when IGCL files new disclosures

Track IGCL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track IGCL — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd